-
Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma
•
Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced the completion of a market approval filing with the National Medical Products Administration (NMPA) in China for the antibody drug conjugate (ADC) enfortumab vedotin, marketed as Padcev in the US. The filing seeks approval for…
-
HealiRNA Secures RMB 100 Million in Pre-Series A Funding for Nucleic Acid Drug Development
•
China-based nucleic acid drug specialist Suzhou HealiRNA has reportedly raised over RMB 100 million (USD 14.35 million) in a pre-Series A financing round. The round was led by MING Bioventures, with additional investments from Shunwei Capital, China-Singapore Suzhou Industrial Park Private Equity Management Co., Ltd, and existing investor Sequoia Capital…
-
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
•
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a clinical study for its B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. The study was approved in China in September last year. This marks a significant milestone in the development of the drug, which is designed to treat…
-
Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Autoimmune Therapies
•
China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million) in a Series A financing round, led by Bainuo Capital. Existing investor Hankang Capital also participated in the round. The proceeds will be used to support research and development and clinical studies for multiple autoimmune…
-
Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development
•
Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by HM Capital, with additional funding from Northern Lights Venture Capital. The proceeds will be used to support clinical studies, new product research…
-
Haihe Pharma’s Glumetinib Gains Conditional NMPA Approval for NSCLC
•
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has received conditional market approval from the National Medical Products Administration (NMPA). This small-molecule MET inhibitor is now approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET14 exon hopping, marking a significant advancement in…
-
AmVision Biotech Secures Nearly $14.34M in Series A+ for Ophthalmology Innovations
•
AmVision Biotech, a leading ophthalmology device platform company based in Guangzhou, has reportedly secured close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The round was led by Green Pine Capital Partners, with participation from ZDVC and existing investor HM Capital, among others. This significant…
-
JW Therapeutics Launches Carteyva Clinical Study for High-Risk Lymphoma
•
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its Carteyva (relmacabtagene autoleucel injection) in the treatment of first-line high-risk large B-cell lymphoma. A significant milestone was reached with the completion of reinfusion therapy for the first patient. Previous Study Outcomes and Current Trial DesignThe…
-
Chongqing Evaheart Secures Near $100M in Series A for Heart Failure Platform
•
Chongqing Evaheart Medical Device Co., Ltd has reportedly secured close to USD 100 million in a Series A financing round. The round was led by Sinovac, with significant contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The funds raised will be directed towards the development…
-
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen’s…
-
Haihe Pharma’s Glumetinib Receives Conditional Approval for NSCLC Treatment
•
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has obtained conditional market approval from the National Medical Products Administration (NMPA). The small-molecule MET inhibitor is now approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET14 exon hopping. Development and Clinical FindingsGlumetinib, co-developed…
-
AmVision Biotech Secures RMB 100 Million in Series A+ Financing for Ophthalmology Innovation
•
AmVision Biotech, an ophthalmology device platform company based in Guangzhou, has reportedly raised close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The funding was led by Green Pine Capital Partners, with contributions from ZDVC and existing investor HM Capital, among others. This investment will…
-
JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
•
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its Carteyva (relmacabtagene autoleucel injection) in first-line high-risk large B-cell lymphoma. The first patient has already completed reinfusion therapy, marking a significant step in the study’s progress. Previous Study ResultsThe pivotal RELIANCE study previously demonstrated that…
-
Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac
•
Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in a Series A financing round led by Sinovac, with contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The proceeds will be used to develop and construct a comprehensive heart failure…
-
HQ Pharma and Shanxi HCXF Partner to Expand Oral Soluble Film R&D and Production
•
China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand their one-stop oral soluble film research and development (R&D) and production services. The collaboration aims to enhance their capabilities in this innovative drug delivery system, with no financial details disclosed. Advantages of Oral Soluble FilmsOral…
-
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). The agreement grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite platform and…
-
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
•
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical Co., Ltd, focusing on the over-active bladder (OAB) therapy Gemtesa (vibegron). This strategic agreement grants Sumitomo development, manufacturing, and commercialization rights to vibegron in key Asian markets, including Taiwan and Hong Kong in China, Singapore,…
-
Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies
•
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The…
-
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
•
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607). The partnership aims to accelerate the development of Akeso’s cadonilimab (AK104) in combination with Shanghai Pharmaceuticals’ SPH4336 for the treatment of well-differentiated liposarcoma (WDLS) and dedifferentiated liposarcoma (DDLS). About…
-
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
•
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from the Committee on Foreign Investment in the United States (CFIUS) for the all-cash acquisition by invoX Pharma Limited, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177). This clearance is a significant step towards…
